Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short
Shares of Incyte slumped Monday after the drugmaker's fourth-quarter adjusted profit and 2025 sales forecasts missed analysts' expectations.
The company's sales topped estimates for the fourth quarter as its two biggest drugs, Jakafi and Opzelura, grew year-over-year.
Despite the strong latest quarter for the two drugs, Incyte's projections for their 2025 sales in 2025 fell short of estimates.Incyte (INCY) stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of its key medications fell short of analysts' estimates.
Incyte's Q4 sales of $1.18 billion rose 16% year-over-year and topped Visible Alpha estimates as sales of its two biggest drugs, Jakafi and Opzelura, grew 11% to $773.1 million and 48% to $161.6 million, respectively.
The company's adjusted earnings per share (EPS) of $1.43 rose from $1.06 last year but came in 10 cents below expectations.
Incyte's outlook for Jakafi and Opzelura sales also came in below expectations. The company expects sales of Jakafi, which prevents overproduction of red blood cells, to bring in between $2.925 billion and $2.975 billion for 2025, with sales of the skin cream Opzelura forecast at between $630 million to $670 million.
Entering Monday, analysts expected 2025 sales of the two drugs to come in at roughly $3.34 billion and $672.2 million, respectively.
Shares of Incyte were down more than 6% Monday afternoon but are still up roughly 20% over the last 12 months.
Read the original article on Investopedia
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq futures slip as investors assess easing trade tensions
US stock futures slipped as Wall Street assessed easing tensions between the US and key trading partners as well as softening inflation. Futures attached to the Dow Jones Industrial Average (YM=F) dipped 0.1%. Futures attached to the benchmark S&P 500 (ES=F) and the tech-heavy Nasdaq 100 (NQ=F) fell 0.2%. On Wednesday, Treasury Secretary Scott Bessent told Congress it is "highly likely" that countries engaging in trade negotiations with the US would see an extension of a tariff pause that is already in place on President Trump's most sweeping duties. Bessent's comment came after he returned from London on Tuesday, where representatives from US and China announced the countries had agreed to a proposal that would address critical trade disputes. Read more: The latest on Trump's tariffs Stocks wobbled during the day Wednesday amid the evolving trade news as well as the latest Consumer Price Index (CPI) report, which showed easing inflation pressures. The data puts the Federal Reserve in a tight spot ahead of its policy meeting next week, though analysts expect officials to maintain their wait-and-see approach to interest rate cuts as tariff uncertainty lingers. On Thursday, investors will receive fresh data on wholesale inflation with the release of the Producer Price Index (PPI) report. As earnings season wraps up, Adobe (ADBE) will also share its results. Sign in to access your portfolio
Yahoo
38 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Miami Herald
an hour ago
- Miami Herald
Stocks sputter after surprising inflation, China trade news
The stock market needs a new catalyst. Until now, the S&P 500's rally since early April was built on the potential for sellers to be caught off guard by surprising trade deals. Since the benchmark index has rallied 21% after Trump paused reciprocal tariffs on April 9, fewer investors will likely be surprised by developments, and many may be disappointed with outcomes. The possibility that tariff deals may be baked into stock prices appeared when a softer-than-expected May inflation report, alongside what should've been positive China trade news, fell flat. The S&P 500 posted early gains on the news, but reversed to close lower by the end of trading. Related: CPI inflation report resets interest rate cut bets The culprit? While CPI showed inflation was relatively tame last month, most still believe tariffs will cause inflation to reassert itself later this year. Advancing China and the U.S. negotiations are encouraging, but President Trump's comments regarding China tariffs are disheartening. The "meh" reaction to the inflation and China trade news caught the attention of veteran hedge fund manager Doug Kass. Kass has been tracking the markets professionally since the 1970s, and he's the former research director for Leon Cooperman's Omega Advisors, one of the most famous hedge funds in history. After witnessing today's reaction to the news, Kass offered up a frank opinion that may frustrate some investors. Image source: Goodney/Bloomberg via Getty Images The Federal Reserve's mission is to balance inflation and unemployment. It does this by adjusting the Fed Funds Rate. When it increases rates, economic activity slows, crimping inflation but increasing unemployment. When it lowers rates, GDP expands, lowering unemployment but increasing inflation. The dual mandate means that the Fed is in a pickle this year. After the most hawkish monetary policy since the 1980s caused inflation to drop below 3% from over 8% in 2022, the Fed switched gears, cutting rates in September, November, and December to lower unemployment, which has risen to 4.2% from 3.4% in 2023. Related: Billionaire fund manager sends strong message on Fed Chair Powell's future Hopes were for more cuts in 2025, but Fed Chair Powell was forced to pause additional reductions amid sticky inflation and the threat of tariffs driving prices higher. As a result, many Wall Street economists have gone from expecting many cuts this year to none. The CPI report showed that inflation in May only inched up 0.1% month over month, less than the 0.2% predicted. However, headline CPI showed inflation of 2.4% year over year last month, up from 2.3% in April. Meanwhile, core CPI, excluding volatile energy and food prices, was up 2.8% in May, matching April. That's undoubtedly not barn-burning progress. Nevertheless, some latched onto the lower-than-expected increase as evidence that the tariff impact on inflation is overblown, helping stocks in early action. Also contributing to optimism was news out of London that a meeting between Chinese and U.S. officials, including Treasury Secretary Scott Bessent, had led to progress in uncorking supplies of rare earth minerals necessary for EVs and other next-gen technology. President Trump heralded the deal, saying, "OUR DEAL WITH CHINA IS DONE, SUBJECT TO FINAL APPROVAL WITH PRESIDENT XI AND ME. FULL MAGNETS, AND ANY NECESSARY RARE EARTHS, WILL BE SUPPLIED, UP FRONT, BY CHINA. LIKEWISE, WE WILL PROVIDE TO CHINA WHAT WAS AGREED TO, INCLUDING CHINESE STUDENTS USING OUR COLLEGES AND UNIVERSITIES." More Economic Analysis: Hedge-fund manager sees U.S. becoming GreeceA critical industry is slamming the economyReports may show whether the economy is toughing out the tariffs However, details were scant, and Trump threw some cold water onto hopes that a trade deal would ease tariffs on Chinese goods, which already currently stand near 55% all-in. "WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%," he said on Truth Social. Doug Kass has seen more than his share of good and bad tapes. He's survived the 1970s inflation, 1980s skyrocketing interest rates, the S&L crisis, Internet boom and bust, the Great Recession, Covid, and 2022's bear market. Related: Fed official revamps interest-rate cut forecast for rest of this year His experience led to him correctly predicting this year's steep sell-off and his accurate bet that stocks would bounce in early April after the drop. He isn't convinced that the latest inflation progress is bullish for the S&P 500. "The market has likely already discounted a better than expected Core CPI," wrote Kass on TheStreet Pro. "Market participants may interpret this number as being less exciting for equities because companies/manufacturers are likely eating the higher costs/tariffs, leading to concerns about lower margins and profits over the balance of the year." Kass says that "swings in the trade balance" show importers stockpiled inventory ahead of Trump's April 2 "Liberation Day" tariff announcements. As a result, May data still reflects inventory brought in before tariffs hit. "When that inventory runs out, they will likely have to put through price hikes and inflation will heat up," said Kass. Kass is similarly unimpressed by the outcome of the China meeting. "The China/U.S. tariff meeting ended up being a complete non-event (with no evidence of lowering tariffs)," wrote Kass. Absent tariff relief, companies absorbing at least some additional costs will see earnings come under pressure. And since earnings growth is a cornerstone of stock prices and tariffs don't seem destined to retreat further anytime soon, there may be little impetus to support a rip-roaring rally. Related: Veteran fund manager revamps stock market forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
